Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis.
Animals
Anti-Inflammatory Agents
/ pharmacology
Cell Line
Central Nervous System
/ pathology
Disease Models, Animal
Encephalomyelitis, Autoimmune, Experimental
/ immunology
Female
Glutamates
/ metabolism
Indans
/ pharmacology
Interleukin-1beta
/ metabolism
Mice, Inbred C57BL
Microglia
/ drug effects
Multiple Sclerosis
/ immunology
Neostriatum
/ drug effects
Oxadiazoles
/ pharmacology
RNA, Messenger
/ genetics
Sphingosine-1-Phosphate Receptors
/ agonists
Synapses
/ drug effects
Synaptic Transmission
/ drug effects
T-Lymphocytes
/ immunology
Thiophenes
/ pharmacology
beta-Alanine
/ analogs & derivatives
A971432
AUY954
S1P1
S1P5
T lymphocytes
experimental autoimmune encephalomyelitis (EAE)
glutamate synaptic dysfunction
microglia
neuroinflammation
ozanimod
pro-inflammatory cytokines
sphingosine-1-phosphate receptors
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
22 05 2020
22 05 2020
Historique:
received:
20
04
2020
revised:
14
05
2020
accepted:
18
05
2020
entrez:
28
5
2020
pubmed:
28
5
2020
medline:
26
2
2021
Statut:
epublish
Résumé
Future treatments of multiple sclerosis (MS), a chronic autoimmune neurodegenerative disease of the central nervous system (CNS), aim for simultaneous early targeting of peripheral immune function and neuroinflammation. Sphingosine-1-phosphate (S1P) receptor modulators are among the most promising drugs with both "immunological" and "non-immunological" actions. Selective S1P receptor modulators have been recently approved for MS and shown clinical efficacy in its mouse model, the experimental autoimmune encephalomyelitis (EAE). Here, we investigated the anti-inflammatory/neuroprotective effects of ozanimod (RPC1063), a S1P
Identifiants
pubmed: 32455907
pii: cells9051290
doi: 10.3390/cells9051290
pmc: PMC7291065
pii:
doi:
Substances chimiques
AUY 954
0
Anti-Inflammatory Agents
0
Glutamates
0
Indans
0
Interleukin-1beta
0
Oxadiazoles
0
RNA, Messenger
0
Sphingosine-1-Phosphate Receptors
0
Thiophenes
0
beta-Alanine
11P2JDE17B
ozanimod
Z80293URPV
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Nat Rev Immunol. 2015 Sep 15;15(9):545-58
pubmed: 26250739
J Neurosci. 2017 Jan 18;37(3):546-561
pubmed: 28100738
Chem Biol. 2006 Nov;13(11):1227-34
pubmed: 17114004
Neuropharmacology. 2017 Feb;113(Pt B):597-607
pubmed: 27825807
Mol Neurobiol. 2018 Mar;55(3):2320-2332
pubmed: 28343295
Cells. 2019 Jan 07;8(1):
pubmed: 30621015
Neuropathol Appl Neurobiol. 2014 Aug;40(5):564-78
pubmed: 23551178
Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14230-5
pubmed: 22891354
Neuropathol Appl Neurobiol. 2020 Feb;46(2):160-170
pubmed: 31125471
Br J Pharmacol. 2016 Jun;173(11):1778-92
pubmed: 26990079
CNS Drugs. 2015 Jul;29(7):565-75
pubmed: 26239599
Br J Pharmacol. 2012 Feb;165(4):861-9
pubmed: 21740406
Clin Exp Immunol. 2010 Oct;162(1):1-11
pubmed: 20682002
Lancet Neurol. 2016 Sep;15(10):1089-102
pubmed: 27571160
Clin Neurophysiol. 2015 Jan;126(1):165-9
pubmed: 25022794
Int J Dev Neurosci. 2003 Dec;21(8):431-43
pubmed: 14659994
J Neuroinflammation. 2016 Feb 08;13:31
pubmed: 26856814
Ann Neurol. 2014 Sep;76(3):325-37
pubmed: 25043204
Lancet. 2018 Mar 31;391(10127):1263-1273
pubmed: 29576505
J Neuroimmunol. 2013 Mar 15;256(1-2):13-8
pubmed: 23290828
Neurochem Res. 2017 Feb;42(2):686-696
pubmed: 27943027
J Neurochem. 2016 Mar;136(5):971-80
pubmed: 26662167
Pharmacol Res. 2013 Jan;67(1):1-9
pubmed: 23073075
J Med Chem. 2015 Dec 10;58(23):9154-70
pubmed: 26509640
Neurobiol Dis. 2015 Feb;74:347-58
pubmed: 25511803
J Neuroinflammation. 2016 Aug 26;13(1):207
pubmed: 27566665
Nat Rev Drug Discov. 2010 Nov;9(11):883-97
pubmed: 21031003
J Neuroimmunol. 2018 May 15;318:1-7
pubmed: 29606295
J Neurochem. 2007 Aug;102(4):1151-61
pubmed: 17488279
Ann Neurol. 2014 Aug;76(2):269-78
pubmed: 25043416
Neurotherapeutics. 2017 Oct;14(4):859-873
pubmed: 28812220
J Neurosci. 2009 Mar 18;29(11):3442-52
pubmed: 19295150
Brain. 2009 May;132(Pt 5):1175-89
pubmed: 19339255
Cell Death Differ. 2010 Jul;17(7):1083-91
pubmed: 19927157
Lancet Neurol. 2019 Nov;18(11):1021-1033
pubmed: 31492652
Acta Neuropathol. 2015 Aug;130(2):279-95
pubmed: 25920452
J Biol Chem. 2007 Mar 23;282(12):9082-9
pubmed: 17237497
Lancet Neurol. 2020 Apr;19(4):336-347
pubmed: 32059809
Brain Behav Immun. 2011 Jul;25(5):947-56
pubmed: 20940040
Ann Neurol. 2012 Jan;71(1):76-83
pubmed: 22275254
Nat Rev Neurol. 2015 Dec;11(12):711-24
pubmed: 26585978
CNS Drugs. 2017 Apr;31(4):289-305
pubmed: 28247239
J Neurosci. 2013 Jul 17;33(29):12105-21
pubmed: 23864696
Neurology. 2003 Oct 28;61(8):1113-20
pubmed: 14581674
Neurobiol Dis. 2012 May;46(2):414-24
pubmed: 22349452
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):751-6
pubmed: 21177428
N Engl J Med. 2018 Jan 11;378(2):169-180
pubmed: 29320652
Hum Mol Genet. 2018 Jul 15;27(14):2490-2501
pubmed: 29688337
J Neuroinflammation. 2015 May 08;12:86
pubmed: 25953296
Lancet Neurol. 2019 Nov;18(11):1009-1020
pubmed: 31492651
J Neuroimmunol. 2018 May 15;318:103-113
pubmed: 29530550